Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results